Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02969109 · ClinicalTrials.gov registry record
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
A clinical trial of Non-muscle Invasive Bladder Cancer, sponsored by Genomic Health®.
- Completed
- Registry status
- 417
- Enrollment target
- 1
- Study location
NCT02969109: Completed study of Non-muscle Invasive Bladder Cancer, sponsored by Genomic Health®.
NCT02969109 is a study of Non-muscle Invasive Bladder Cancer that has completed, run by Genomic Health®. The registered enrollment target is 417 participants, above the 213-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (96% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02969109, a study of Non-muscle Invasive Bladder Cancer, has completed, sponsored by Genomic Health®.
- COMPLETED
- Registry status
- 417 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.
Conditions Studied
Study Locations (1)
Minnesota
- Institute for Prostate and Urologic Cancers - University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2015-10 |
| Est. Completion | 2018-09-18 |
What the finished NCT02969109 record still lists
NCT02969109 is an observational study that tracks outcomes without assigning an intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap, above the 213-participant average among 30 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (96% higher).
The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT02969109 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02969109 about?
NCT02969109 is a clinical study titled "Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer". A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder cancer.
What is the current status of trial NCT02969109?
This trial is currently completed. The enrollment target is 417 participants. The study started on 2015-10. Estimated completion is 2018-09-18.
What conditions does trial NCT02969109 study?
This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.
Who is sponsoring clinical trial NCT02969109?
This trial is sponsored by Genomic Health®, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02969109 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-muscle Invasive Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02969109's enrollment target sits among peer trials
417 6th of 30 higher than 25 of 30 other Non-muscle Invasive Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-muscle Invasive Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RECRUITING · Phase 1
-
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
RECRUITING · Phase 1
-
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RECRUITING · Phase 2
-
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
RECRUITING · Phase 2
-
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia